Gainers
Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.
The TRials with EblasaKimab in Dupilumab eXperienced atopic dermatitis patients (TREK-DX) study will evaluate eblasakimab in a patient population with few safe treatment options
The study will enroll 75
Gainers
ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million.
ASLAN Pharmaceuticals (NASDAQ:ASLN) announced the presentation of new translational eblasakimab data at the Annual European Society for Dermatological Research (ESDR) Meeting. …
ASLAN Pharmaceuticals (NASDAQ: ASLN) today announced the presentation of new translational eblasakimab data at the 51st Annual European Society for Dermatological Research (ESDR) Meeting.
Gainers
OpGen (NASDAQ:OPGN) shares rose 20.6% to $0.52 during Monday's after-market session. This security traded at a volume of 927.4K shares come close, making up 324.6% of its average volume over the last 100 days. The company's market cap stands at $25.0 million.
BelleTorus Corporation (“Belle.ai”) and ASLAN Pharmaceuticals (NASDAQ:ASLN), today announced that ASLAN has licensed belleStudy™ digital image capture software in support of ASLAN’s clinical